5 41 891 u 50300 dmi 2060 out 42 46 88 2 usa

Unformatted text preview: .3 P 75^300 IP 20^80 Out 29 30 30 89 1 USA 16 F LUOX E T IN E v . P L A C E B O A N D T C A s I N S HO R T-T E R M T R E AT M E N T OF D E P R E S S I ON v. IN HOR 423 4 24 63 4 28, 96.5 U 50^150 TCA 24, 80.0 22, 75.9 P 75^150 IP 20 Out 30 29 59 2 2 21, 70.0 18, 54.5 P 50^225 DT 40^80 In/Out 30 33 63 5 3 23, 76.7 16, 57.1 U 100^200 DT 20^40 In/Out 30 28 58 3 4 14, 93.3 14, 93.3 P 50^175 CI 20^60 In 15 15 30 1 5 26, 68.4 25, 65.8 U 50^200 D 20^60 In/Out 38 38 76 1 6 16, 76.2 20, 95.2 U 100^250 AT 40^80 In/Out 21 21 42 14 7 28, 73.7 24, 64.9 U 75^300 AT 20^80 specified Not- 38 37 75 1 8 12, 85.7 11, 84.6 U 50^175 IP 20^60 Out 14 13 27 1 9 15, 100.0 15, 100.0 U 50^175 IP 20^60 In 15 15 30 1 10 Non-USA Non-USA Non-USA Non-USA Non-USA Non-USA Non-USA Non-USA AT, amitriptyline; IP, imipramine; D, doxepin; DT, dothiepin; CI, clomipramine; M, maprotiline. 30, 88.2 Fluoxetine Completers (n, %) Published (P)/unpublished (U) Dosage range (mg) M 40^80 Fluoxetine dosage range (mg) TCA Out 34 Fluoxetine TCA Status (in-patient/out-patient) 29 Total No. of patients 1 Non-USA Non-USA Description of the 14 non-USA trials (Europe and elsewhere) of fluoxetine v. tricyclic antidepressant (TCA) in major depression (DSM^III) No. of investigators Variables Table 1b T able 12, 80.0 9, 81.8 U 50^175 AT 20^60 In 15 11 26 1 11 Non-USA 10, 58.8 15, 100.0 U 50^175 IP 20 In/Out 17 15 32 1 12 Non-USA 12, 80.0 15, 100.0 P 50^175 IP 20 In/Out 15 15 30 1 13 Non-USA 19, 59.4 18, 60.0 P 50^200 CI 20 In 32 30 62 41 14 Non-USA B E CH E T AL F LUOX E T IN E v . P L A C E B O A N D T C A s I N S HO R T-T E R M T R E AT M E N T OF D E P R E S S I ON v. IN HOR received placebo and 686 had received TCAs (either amitriptyline, desipramine, doxepin, imipramine, or nortriptyline). A total of 96 patients were excluded, per our protocol, because they had been randomised to receive a fixed dose of 5 mg/ day of fluoxetine. Therefore, data for a total of 3447 patients were included in the meta-analyses (1914 in the fluoxetinetreated group, 847...
View Full Document